• Japanese
  • Korean
  • Chinese
Cover Image

Global Markets for Infectious Disease Treatments

Abstract

REPORT HIGHLIGHTS

This report provides:

  • An overview of the global market for infectious disease treatments, with a focus on the growth in demand for newer pharmaceutical treatments, vaccines, and environmental products
  • Analyses of global market trends, with data from 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017
  • Discussion of the increasing concern regarding antibiotic-resistant organisms and their sometimes-fatal effects on humans
  • Examination of technological developments, future trends, and emerging opportunities
  • Assessments of the current state of infectious diseases on a global basis, broken down by type of disease (i.e., bacterial, viral, parasitic, and fungal) and appropriate treatments, both current and anticipated, and by geographic region
  • Patent analysis
  • Comprehensive company profiles of major players.

image1

REPORT SCOPE

INTRODUCTION

STUDY GOALS AND OBJECTIVES

Infectious diseases are one of the major causes of global morbidity and mortality. Viral, bacterial, parasitic and fungal diseases have plagued humankind for centuries, and our attempts to control these diseases have met with great success. Diseases that were once death sentences are now chronic and manageable diseases.

But as with every ongoing story, microbes have transformed themselves to outwit current medications, and the battle to rid humans of the most virulent of diseases continues. With the constant combining and reinvention of microbes comes an urgent need for improved antibiotic and viral medications to sustain the progress made in addressing the most aggressive of infectious diseases.

Under these circumstances, there is need for a current and comprehensive report on infectious diseases covering diagnosis, treatment, demand trends, opportunities, and emerging technologies.

This study gives a clear, quantitative picture of the supply-and-demand scenario, and it highlights the technological and investment opportunities in the field.

REASONS FOR DOING THE STUDY

This report provides the reader with a detailed analysis of the global infectious disease market, with emphasis on seven major infectious diseases (i.e., human immunodeficiency virus/acquired immunodeficiency virus [HIV/AIDS]; hepatitis A, B, C; malaria, rotavirus/diarrhea; measles; pneumonia; and tuberculosis [TB]).

The report also discusses technological developments, future trends, and emerging opportunities. The major objectives of this study are:

  • Assessing the current state of infectious diseases on a global basis.
  • Identifying the driving factors for demand of new diagnostic and pharmaceutical products.
  • Estimating current and future market sizes for diagnostic and pharmaceutical infectious disease products.
  • Estimating the current global supply-and-demand scenario, by disease type and geographical regions.
  • Identifying factors that influence the industry and proposing market opportunities.

SCOPE OF REPORT

The market report organizes information from diverse sources into a cohesive unit that includes an overview, global implications of infectious diseases, infectious diseases by type, treatment and prevention, emerging pharmaceutical and diagnostic products, and an applicable patents section. Information is organized by type of infectious disease (i.e., bacterial, viral, parasitic) and appropriate treatments, both current and anticipated.

INTENDED AUDIENCE

This updated version on the infectious disease market and technologies will be a valuable tool for decision makers and manufacturers in both the diagnostic and the pharmaceutical treatment industries. Individuals at research foundations, manufacturing companies, and university laboratories will find valuable information on the global diagnostic product and pharmaceutical industries. This information will also be useful for individuals involved in strategic planning and marketing and sales development.

The audience will obtain a broad view of the social and economic consequences of infectious diseases. Additionally, emphasis on the type of disease, major players in the marketplace, market conditions, and current and projected revenues will be provided.

METHODOLOGIES AND INFORMATION SOURCES

The data for this report were gathered from primary and secondary sources. Sources include information obtained from industry analysis, manufacturers, academic and trade journals, and industry associations. Additional sources include the U.S. Patent and Trademark Office (USPTO), U.S. Securities and Exchange Commission (SEC) filings, the World Health Organization (WHO), the Centers for Disease Control (CDC), the Mayo Clinic, the Pharmaceutical Research and Manufacturing Association, and UNAIDS.

Where precise information was not available, a projection was made using reasonable assumptions and estimates based on historical data. All market data are based on manufacturers' sales.

ANALYST CREDENTIALS

Peggy Lehr is the BCC Research analyst for this report. Ms. Lehr holds a BS in Journalism from the University of Colorado, Boulder, and an MS in Communication from the University of Denver. Ms. Lehr has worked as a researcher, editor, and publisher within the publishing industry for both for-profit and not-for-profit organizations. She is the author of several BCC reports dealing with healthcare, pharmaceuticals, and agriculture.

Table of Contents

Chapter- 1: INTRODUCTION - Complimentary

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • METHODOLOGIES AND INFORMATION SOURCES
  • ANALYST CREDENTIALS
  • RELATED BCC REPORTS
  • BCC ON-LINE SERVICES
  • DISCLAIMER

Chapter- 2: SUMMARY

  • Table Summary : PROJECTED MARKET FOR INFECTIOUS DISEASES DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS BY TYPE, THROUGH 2017
  • Figure Summary : PERCENTAGE OF MARKET SHARE FOR INFECTIOUS DISEASE DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS BY GEOGRAPHIC REGION, 2012 AND 2017

Chapter- 3: OVERVIEW OF THE GLOBAL STATE OF INFECTIOUS DISEASE DIAGNOSIS, VACCINES, AND TREATMENT

  • TOP GLOBAL CAUSES OF DEATH
  • MAJOR INFECTIOUS DISEASES
  • HISTORICAL IMPACT OF INFECTIOUS DISEASES
  • TREATMENTS FOR INFECTIOUS DISEASES
  • GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET
  • TYPES OF DIAGNOSTIC TESTING
  • GLOBAL MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
  • GLOBAL INFECTIOUS DISEASE VACCINE MARKET
  • THE GLOBAL INFECTIOUS DISEASE PHARMACEUTICAL MARKET
  • PROJECTIONS FOR GLOBAL INFECTIOUS DISEASE PRODUCTS BY TYPE AND DISEASE
  • VACCINE OPPORTUNITIES
  • PHARMACEUTICAL OPPORTUNITIES
  • THE EMERGENCE OF GENE THERAPY
  • MERGERS AND ACQUISITIONS

Chapter- 4: VACCINES-THE PRESENT AND THE FUTURE

  • MARKET FOR HUMAN INFECTIOUS DISEASE VACCINES
  • TYPES OF VACCINES
  • IMMUNITY
  • VIRAL DISEASES PREVENTED BY VACCINE
  • BACTERIAL DISEASES PREVENTED BY VACCINE
  • VACCINATION SCHEDULES FOR CHILDREN
  • CONCERNS REGARDING VACCINATION IN CHILDHOOD
  • VACCINE PRODUCTION
  • VACCINE MANUFACTURERS
  • TOP- SELLING VACCINES OF 2011
  • REGIONAL ANALYSIS
  • TRENDS IN VACCINE DEVELOPMENT

Chapter- 5: VIRAL INFECTIOUS DISEASES

  • GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS
  • HEPATITIS B AND C
  • HERPES SIMPLEX VIRUS
  • HEPATITIS B AND C
  • HIV/AIDS
  • HUMAN PAPILLOMAVIRUS
  • INFLUENZA A AND B
  • MEASLES
  • PNEUMONIA
  • ROTAVIRUS
  • RSV
  • VIRAL DIAGNOSTIC PRODUCTS
  • VIRAL PHARMACEUTICAL PRODUCTS

Chapter- 6: BACTERIAL INFECTIOUS DISEASES AND THE SPECTER OF ANTIBIOTIC RESISTANCE

  • NEGLECTED TROPICAL BACTERIAL INFECTIOUS DISEASES
  • MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS
  • MARKET FOR BACTERIAL INFECTIOUS DISEASE DIAGNOSTICS
  • MARKET FOR BACTERIAL INFECTIOUS DISEASES PHARMACEUTICALS
  • NOTABLE BACTERIAL DISEASES
  • ANTIBIOTIC DEVELOPMENT
  • ANTIBIOTIC RESISTANCE
  • PRIMARY REASONS FOR ANTIBIOTIC RESISTANCE
  • INTERNATIONAL SURVEILLANCE OF ANTIBIOTIC-RESISTANT ORGANISMS
  • RESISTANCE BY CLASS OF ANTIBIOTIC
  • INCIDENCES OF ANTIBIOTIC RESISTANCE
  • MAJOR ANTIBIOTIC-RESISTANT ORGANISMS
  • REGIONAL ANALYSIS

Chapter- 7: PARASITIC INFECTIOUS DISEASES

  • NEGLECTED TROPICAL PARASITIC INFECTIOUS DISEASES
  • CLIMATE CHANGE AND VECTOR-BORNE DISEASES
  • MALARIA
  • REGIONAL ANALYSIS
  • MARKET FOR ANTIPARASITIC PHARMACEUTICALS

Chapter- 8: EMERGING TECHNOLOGY AND PHARMACEUTICALS

  • HEPATITIS C
  • INFLUENZA
  • HSV
  • MALARIA
  • ANTIBIOTIC RESISTANCE
  • PHARMACEUTICAL TREATMENT PRODUCT PIPELINE

Chapter- 9: PATENT ANALYSIS

  • PHARMACEUTICAL PATENTS, BY PATENT NUMBER, DISEASE, COMPANY, DESCRIPTION AND APPROVAL DATE
  • DIAGNOSTIC PATENTS ISSUED, BY COMPANY, APPROVAL DATE, AND DISEASE
  • PATENTS ISSUED BY COMPANY
  • PATENTS ISSUED BY COUNTRY
  • INFECTIOUS DISEASES PATENTS ISSUED, BY DISEASE
  • INFECTIOUS DISEASES PATENTS, BY YEAR

Chapter- 10: COMPANY PROFILES

  • ABBOTT LABORATORIES
  • ALERE
  • ALFA SCIENTIFIC DESIGNS
  • ATLAS LINK BIOTECH CO., LTD.
  • ASTRA ZENECA
  • BAXTER HEALTHCARE
  • BAYER AG
  • BECTON DICKINSON
  • BIO-RAD LABORATORIES
  • BOEHRINGER INGELHEIM GMBH
  • BRISTOL-MYERS SQUIBB COMPANY
  • CEPHEID
  • CRUCELL NV
  • CUBIST PHARMACEUTICALS
  • DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS INC.
  • DIASORIN
  • ENANTA PHARMACEUTICALS
  • ENZO BIOCHEM
  • FIRST DIAGNOSTIC LLC
  • GILEAD SCIENCES INC.
  • GLAXOSMITHKLINE
  • HOLOGIC GEN-PROBE INC.
  • HOME ACCESS HEALTH INC.
  • IDENIX PHARMACEUTICALS
  • IMMUNOSTICS
  • IND DIAGNOSTIC INC.
  • INVERNESS MEDICAL INNOVATIONS (SEE ALERE)
  • IPCA LABORATORIES
  • JANSSEN THERAPEUTICS (FORMERLY TIBOTEC THERAPEUTICS)
  • MANGALAM DRUGS & ORGANICS LTD.
  • MEDMIRA INC
  • MERCK & COMPANY INC.
  • MERIDIAN BIOSCIENCE
  • NOVARTIS CORPORATION
  • ORASURE TECHNOLOGIES INC.
  • ORTHO CLINICAL DIAGNOSTICS
  • PARATEK PHARMACEUTICALS
  • PFIZER INC
  • PRINCETON BIOMEDITECH CORPORATION
  • PROTEIN SCIENCES CORPORATION
  • QUIDEL
  • QUIGEN N.V.
  • ROCHE LABORATORIES (HOFFMANN-LA ROCHE INC.)
  • RIB-X PHARMACEUTICALS
  • ROMARK LABORATORIES
  • SANOFI PASTEUR
  • SCICLONE PHARMACEUTICALS
  • SHANGHAI KEHUA BIO-ENGINEERING CO., LTD.
  • STANDARD DIAGNOSTICS INC
  • TETRAPHASE PHARMACEUTICALS
  • TRINITY BIOTECH PLC
  • VERTEX PHARMACEUTICALS
  • VIIV HEALTHCARE

List of Tables

  • Summary Table : PROJECTED MARKET FOR INFECTIOUS DISEASES DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS BY TYPE, THROUGH 2017
  • Table 1 : GLOBAL PERCENTAGE OF DEATHS BY TYPE OF DISEASE, CAUSE, INCOME LEVEL
  • Table 2 : SELECTED MAJOR INFECTIOUS DISEASES, WORLDWIDE, 2011
  • Table 3 : VACCINE-PREVENTABLE DISEASE DEATHS IN CHILDREN UNDER 5 YEARS OF AGE BY REGION, 2008
  • Table 4 : PROJECTED GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, THROUGH 2017
  • Table 5 : PROJECTED GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE VACCINE PRODUCTS, THROUGH 2017
  • Table 6 : PROJECTED GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS, THROUGH 2017
  • Table 7 : PROJECTED GLOBAL MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC, VACCINE AND TREATMENT PRODUCTS, THROUGH 2017
  • Table 8 : SELECTED MERGERS AND ACQUISITIONS, 2008-2013
  • Table 9 : PROJECTED GLOBAL MARKET FOR INFECTIOUS DISEASE VACCINES, THROUGH 2017
  • Table 10 : VIRUSES, THE DISEASES THEY CAUSE, AND AVAILABLE VACCINES
  • Table 11 : BACTERIA, THE DISEASES THEY CAUSE, AND AVAILABLE VACCINES
  • Table 12 : IMMUNIZATION SCHEDULE FOR CHILDREN FROM BIRTH TO 6 MONTHS
  • Table 13 : IMMUNIZATION SCHEDULE FOR CHILDREN FROM 12 MONTHS TO 4 TO 6 YEARS
  • Table 14 : IMMUNIZATION SCHEDULE FOR CHILDREN AND ADOLESCENTS FROM 7 TO 18
  • Table 15 : TOP-SELLING INFECTIOUS DISEASE VACCINES WITH APPLICATION, MANUFACTURER AND REVENUE, 2011
  • Table 16 : PROJECTED REGIONAL MARKETS FOR VACCINES, THROUGH 2017
  • Table 17 : PROJECTED AMERICAS MARKET FOR INFECTIOUS DISEASE VACCINES BY REGION, THROUGH 2017
  • Table 18 : PROJECTED AMERICAS MARKET FOR INFECTIOUS DISEASE VACCINES BY DISEASE, THROUGH 2017
  • Table 19 : PROJECTED EMRA MARKET FOR HUMAN INFECTIOUS DISEASE VACCINES, BY REGION, THROUGH 2017
  • Table 20 : PROJECTED EMRA MARKET FOR HUMAN INFECTIOUS DISEASE VACCINES, BY DISEASE, THROUGH 2017
  • Table 21 : PROJECTED ASIAN MARKET FOR HUMAN INFECTIOUS DISEASE VACCINES, BY REGION, THROUGH 2017
  • Table 22 : PROJECTED ASIAN MARKET FOR HUMAN INFECTIOUS DISEASE VACCINES, BY DISEASE, THROUGH 2017
  • Table 23 : PROJECTED GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017
  • Table 24 : PROJECTED GLOBAL MARKET FOR HEPATITIS DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017
  • Table 25 : PROJECTED GLOBAL MARKET FOR HSV DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017
  • Table 26 : CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF GENITAL HERPES BY BRAND NAME, TYPE AND MANUFACTURER, 2012
  • Table 27 : MEDICATIONS USED TO TREAT HSV BY BRAND NAME, GENERIC NAME AND MANUFACTURER
  • Table 28 : PROJECTED GLOBAL MARKET FOR HEPATITIS B AND C DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017
  • Table 29 : HEPATITIS B AND C DIAGNOSTIC PRODUCT MARKET SHARE BY TYPE OF TEST AND REVENUES, 2011
  • Table 30 : CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HEPATITIS B AND C BY BRAND NAME AND MANUFACTURER, 2012
  • Table 31 : HEPATITIS B AND C TREATMENT MANUFACTURER MARKET STANDING, BY REVENUES, 2011
  • Table 32 : MEDICATIONS FOR THE TREATMENT OF HEPATITIS B AND C, 2012
  • Table 33 : PROJECTED GLOBAL MARKET FOR HIV DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017
  • Table 34 : CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HPV BY BRAND NAME, TYPE AND MANUFACTURER, 2012
  • Table 35 : MEDICATIONS USED TO TREAT HPV BY BRAND NAME, GENERIC NAME, AND MANUFACTURER
  • Table 36 : RSV DIAGNOSTIC PRODUCTS BY BRAND NAME, MANUFACTURER AND TYPE 2012
  • Table 37 : PROJECTED GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, THROUGH 2017
  • Table 38 : PROJECTED GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS, THROUGH 2017
  • Table 39 : PROJECTED GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017
  • Table 40 : PROJECTED MARKET FOR VIRAL DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2017
  • Table 41 : PROJECTED MARKET FOR VIRAL PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017
  • Table 42 : PROJECTED AMERICAS MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2017
  • Table 43 : PROJECTED AMERICAS MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017
  • Table 44 : PROJECTED AMERICAS MARKET FOR VIRAL INFECTIOUS DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, BY DISEASE, THROUGH 2017
  • Table 45 : PROJECTED EMRA MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2017
  • Table 46 : PROJECTED EMRA MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017
  • Table 47 : PROJECTED EMRA MARKET FOR VIRAL INFECTIOUS DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, BY DISEASE, THROUGH 2017
  • Table 48 : PROJECTED ASIAN MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2017
  • Table 49 : PROJECTED ASIAN MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017
  • Table 50 : PROJECTED ASIAN MARKET FOR VIRAL INFECTIOUS DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, BY DISEASE, THROUGH 2017
  • Table 51 : NEGLECTED TROPICAL BACTERIAL INFECTIOUS DISEASES
  • Table 52 : PROJECTED GLOBAL MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND TREATMENT PRODUCTS, THROUGH 2017
  • Table 53 : PROJECTED GLOBAL MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTICS, THROUGH 2017
  • Table 54 : PROJECTED GLOBAL MARKET FOR BACTERIAL INFECTIOUS DISEASES PHARMACEUTICALS, THROUGH 2017
  • Table 55 : PROJECTED GLOBAL MARKET FOR TB DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS, THROUGH 2017
  • Table 56 : PROJECTED MARKET FOR TB DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, BY REGION, THROUGH 2017
  • Table 57 : HISTORY OF ANTIBIOTIC DISCOVERY AND APPROVAL
  • Table 58 : ANTIBIOTIC CLASSES AND THEIR MODE OF ACTION
  • Table 59 : ANTIBIOTICS APPROVED FOR USE IN FOOD-PRODUCING ANIMALS IN 2009, BY DRUG CLASS, POUNDS USED, AND PERCENTAGE OF TOTAL
  • Table 60 : ANTIBIOTIC-RESISTANT ORGANISMS AND DRUG CLASSES AFFECTED
  • Table 61 : PROJECTED GLOBAL MARKET FOR BACTERIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017
  • Table 62 : PROJECTED AMERICAS MARKET FOR BACTERIAL DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS, THROUGH 2017
  • Table 63 : BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC PRODUCT MARKET IN THE AMERICAS BY REGION, THROUGH 2017
  • Table 64 : BACTERIAL INFECTION PHARMACEUTICAL PRODUCT MARKET IN THE AMERICAS, BY REGION, THROUGH 2017
  • Table 65 : PROJECTED AMERICAS MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, BY DISEASE, THROUGH 2017
  • Table 66 : PROJECTED EMRA MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017
  • Table 67 : BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC PRODUCT MARKET IN EMRA BY REGION, THROUGH 2017
  • Table 68 : BACTERIAL INFECTIOUS DISEASES PHARMACEUTICAL PRODUCT MARKET IN EMRA BY REGION, THROUGH 2017
  • Table 69 : PROJECTED EMRA MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS BY DISEASE, THROUGH 2017
  • Table 70 : PROJECTED ASIA MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS, THROUGH 2017
  • Table 71 : BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC PRODUCT MARKET IN ASIA BY REGION, THROUGH 2017
  • Table 72 : BACTERIAL INFECTIOUS DISEASES PHARMACEUTICAL PRODUCT MARKET IN ASIA, BY REGION, THROUGH 2017
  • Table 73 : PROJECTED ASIAN MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, BY DISEASE, THROUGH 2017
  • Table 74 : NEGLECTED TROPICAL PARASITIC INFECTIOUS DISEASES
  • Table 75 : ESTIMATED 2010 GLOBAL MALARIA CASES AND ESTIMATED DEATHS, RATE OF DECREASE OF MALARIA DEATHS SINCE 2000, BY REGION*
  • Table 76 : PROJECTED GLOBAL MARKET FOR MALARIAL PREVENTION, DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS, THROUGH 2017
  • Table 77 : PROJECTED GLOBAL MARKET FOR INSECTICIDE-TREATED NETS, THROUGH 2017
  • Table 78 : PROJECTED GLOBAL MARKET FOR MALARIAL DIAGNOSTIC PRODUCTS, THROUGH 2017
  • Table 79 : CURRENT PHARMACEUTICALS FOR TREATMENT OF MALARIA, WITH TREATMENT AND MANUFACTURER, 2012
  • Table 80 : PROJECTED GLOBAL MARKET FOR MALARIAL DRUG TREATMENTS, THROUGH 2017
  • Table 81 : PROJECTED GLOBAL MARKET FORMAL ARIAL PREVENTION, DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017
  • Table 82 : PROJECTED AMERICAS MARKET FOR MALARIAL PREVENTION, DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS, THROUGH 2017
  • Table 83 : MALARIAL PREVENTION PRODUCT MARKET IN THE AMERICAS BY REGION, THROUGH 2017
  • Table 84 : MALARIAL DIAGNOSTIC PRODUCT MARKET IN THE AMERICAS BY REGION, THROUGH 2017
  • Table 85 : MALARIAL PHARMACEUTICAL PRODUCT MARKET IN THE AMERICAS BY REGION, THROUGH 2017
  • Table 86 : PROJECTED EMRA MARKET FOR MALARIAL PREVENTIVE, DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017
  • Table 87 : MALARIAL PREVENTIVE PRODUCT MARKET IN EMRA, BY REGION, THROUGH 2017
  • Table 88 : MALARIAL DIAGNOSTIC PRODUCT MARKET IN EMRA, BY REGION, THROUGH 2017
  • Table 89 : MALARIAL PHARMACEUTICAL PRODUCT MARKET IN THE EMRA, BY REGION, THROUGH 2017
  • Table 90 : PROJECTED ASIA MARKET FOR MALARIAL PREVENTION, DIAGNOSTIC, AND PHARMACEUTICAL TREATMENTS, THROUGH 2017
  • Table 91 : MALARIAL PREVENTION PRODUCT MARKET IN ASIA BY REGION, THROUGH 2017
  • Table 92 : MALARIAL DIAGNOSTIC PRODUCT MARKET IN ASIA BY REGION, THROUGH 2017
  • Table 93 : MALARIAL PHARMACEUTICAL PRODUCT MARKET IN ASIA BY REGION, THROUGH 2017
  • Table 94 : CURRENT ANT PARASITIC PHARMACEUTICALS WITH TRADENAME, GENERIC NAME, MANUFACTURER, AND AREA OF TREATMENT, 2012
  • Table 95 : INFECTIOUS DISEASES PHARMACEUTICAL PRODUCT PIPELINE, BY DISEASE, 2012
  • Table 96 : INFECTIOUS DISEASES PHARMACEUTICAL AND VACCINE PATENTS, BY PATENT NUMBER, DISEASE, COMPANY, PRODUCT DESCRIPTION AND APPROVAL DATE, FEBRUARY 2006 TO FEBRUARY 2013
  • Table 97 : INFECTIOUS DISEASES DIAGNOSTIC PATENTS, BY PATENT NUMBER, DISEASE, COMPANY, PRODUCT DESCRIPTION, AND APPROVAL DATE, MARCH 2005-DECEMBER 2012
  • Table 98 : INFECTIOUS DISEASES PHARMACEUTICAL, VACCINE, AND DIAGNOSTIC PRODUCT PATENTS BY COMPANY, MARCH 2005-FEBRUARY 2013
  • Table 99 : INFECTIOUS DISEASE PRODUCT DIAGNOSIS, VACCINE AND TREATMENT PATENTS BY COUNTRY, JANUARY 2005 TO FEBRUARY 2013
  • Table 100 : PATENTS ISSUED FOR DIAGNOSIS, VACCINE AND TREATMENT OF INFECTIOUS DISEASES, BY DISEASE, MARCH 2005-FEBRUARY 2013
  • Table 101 : NUMBER OF INFECTIOUS DISEASES PATENTS FOR DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS, BY DISEASE AND YEAR, 2005-2013
  • Table 102 : ABBOTT PHARMACEUTICAL PRODUCTS
  • Table 103 : ABBOTT DIAGNOSTIC PRODUCTS
  • Table 104 : ALERE DIAGNOSTIC PRODUCTS
  • Table 105 : ALFA SCIENTIFIC DESIGNS DIAGNOSTIC PRODUCTS
  • Table 106 : ATLAS LINK BIOTECH DIAGNOSTIC PRODUCTS
  • Table 107 : ASTRA ZENECA PHARMACEUTICAL PRODUCTS
  • Table 108 : BAXTER PHARMACEUTICAL PRODUCTS
  • Table 109 : BAYER PHARMACEUTICAL PRODUCTS
  • Table 110 : BECTON DICKINSON DIAGNOSTIC PRODUCTS
  • Table 111 : BIORAD DIAGNOSTIC PRODUCTS
  • Table 112 : BOEHRINGER INGELHEIM PHARMACEUTICAL PRODUCTS
  • Table 113 : BRISTOL-MYERS SQUIBB PHARMACEUTICAL PRODUCTS
  • Table 114 : CEPHEID DIAGNOSTIC PRODUCTS
  • Table 115 : CRUCELL VACCINE PRODUCTS
  • Table 116 : CUBIST PHARMACEUTICAL PRODUCT
  • Table 117 : DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS DIAGNOSTIC PRODUCTS
  • Table 118 : DIAGNOSTIC PRODUCTS
  • Table 119 : ENZO BIOCHEM DIAGNOSTIC PRODUCTS
  • Table 120 : FIRST DIAGNOSTIC PRODUCTS
  • Table 121 : GILEAD SCIENCES PHARMACEUTICAL PRODUCTS
  • Table 122 : GLAXOSMITHKLINE PHARMACEUTICAL/VACCINE PRODUCTS
  • Table 123 : HOLOGIC/GENPROBE DIAGNOSTIC PRODUCTS
  • Table 124 : HOME ACCESS DIAGNOSTIC PRODUCTS
  • Table 125 : IMMUNOSTICS DIAGNOSTIC PRODUCTS
  • Table 126 : IND DIAGNOSTIC PRODUCTS
  • Table 127 : JANSSEN THERAPEUTICS PHARMACEUTICAL PRODUCTS
  • Table 128 : EDMIRA DIAGNOSTIC PRODUCTS
  • Table 129 : MERCK VACCINE PRODUCTS
  • Table 130 : MERCK PHARMACEUTICAL PRODUCTS
  • Table 131 : MERIDIAN BIOSCIENCE DIAGNOSTIC PRODUCTS
  • Table 132 : NOVARTIS DIAGNOSTIC PRODUCTS
  • Table 133 : NOVARTIS PHARMACEUTICAL PRODUCTS
  • Table 134 : ORASURE DIAGNOSTIC PRODUCTS
  • Table 135 : ORTHO CLINICAL DIAGNOSTICS DIAGNOSTIC PRODUCTS
  • Table 136 : PFIZER VACCINE PRODUCTS
  • Table 137 : PFIZER PHARMACEUTICAL PRODUCTS
  • Table 138 : PRINCETON BIOMEDICTECH DIAGNOSTIC PRODUCTS
  • Table 139 : QUIDEL DIAGNOSTIC PRODUCTS
  • Table 140 : QUIGEN DIAGNOSTIC PRODUCTS
  • Table 141 : ROCHE DIAGNOSTIC PRODUCTS
  • Table 142 : ROCHE PHARMACEUTICAL PRODUCTS
  • Table 143 : SANOFI PASTEUR PHARMACEUTICAL PRODUCTS
  • Table 144 : SCICLONE PHARMACEUTICAL PRODUCTS
  • Table 145 : SHANGHAI KEHUA BIO-ENGINEERING DIAGNOSTIC PRODUCTS
  • Table 146 : STANDARD DIAGNOSTICS DIAGNOSTIC PRODUCTS
  • Table 147 : TRINITY BIOTECH DIAGNOSTIC PRODUCTS
  • Table 148 : VERTEX PHARMACEUTICAL PRODUCTS
  • Table 149 : VIIV HEALTHCARE PHARMACEUTICAL PRODUCTS

List of Figures

  • Summary Figure : PERCENTAGE OF MARKET SHARE FOR INFECTIOUS DISEASE DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS BY GEOGRAPHIC REGION, 2012 AND 2017
  • Figure 1 : VACCINE-PREVENTABLE DEATHS IN CHILDREN UNDER FIVE YEARS OF AGE, 2008
  • Figure 2 : VACCINE MANUFACTURING PROCESS
  • Figure 3 : PERCENTAGE OF MARKET SHARE FOR VACCINES BY REGION, 2012 AND 2017
  • Figure 4 : TOP PHARMACEUTICAL MANUFACTURERS IN THE HEPATITIS MARKET AND THEIR MARKET SHARE, 2011
  • Figure 5 : PERCENTAGE OF THE GLOBAL VIRAL DIAGNOSTIC AND PHARMACEUTICAL MARKETS BY REGIONS, 2012 AND 2017
  • Figure 6 : MARKET SHARE OF BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS BY REGION, 2012 AND 2017
  • Figure 7 : GLOBAL MARKET FOR MALARIAL TREATMENTS BY REGION 2012 AND 2017
  • Figure 8 : NUMBER OF INFECTIOUS DISEASES PRODUCT DIAGNOSIS, VACCINE AND TREATMENT PATENTS BY COUNTRY, JANUARY 2005-FEBRUARY 2013
  • Figure 9 : INFECTIOUS DISEASES DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PATENTS BY DISEASE ISSUED BETWEEN MARCH 2005 AND DECEMBER 2012,
Show More
RELATED REPORTS
* Analysis of the Global Infectious Disease Diagnostics Market
  • Published:
  • Sep 23, 2014
  • USD 10000
  • 134 Pages

* Global Infectious Disease Treatment Market 2014-2018
  • Published:
  • Aug 27, 2014
  • USD 3500
  • 150 Pages

* Future Horizons and Growth Strategies in the European Virology and Bacteriology Testing Market 2014: Supplier Shares and Country Forecasts
  • Published:
  • Aug 25, 2014
  • USD 12800
  • 1600 Pages

* Future Horizons and Growth Strategies in the German Virology and Bacteriology Testing Market 2014: Supplier Shares and Country Forecasts
  • Published:
  • Aug 25, 2014
  • USD 4300
  • 983 Pages

* Future Horizons and Growth Strategies in the Global Virology and Bacteriology Testing Market 2014: Supplier Shares and Country Forecasts
  • Published:
  • Aug 25, 2014
  • USD 21100
  • 1900 Pages

* Future Horizons and Growth Strategies in the Japanese Virology and Bacteriology Testing Market 2014: Supplier Shares and Country Forecasts
  • Published:
  • Aug 25, 2014
  • USD 5700
  • 976 Pages

* Future Horizons and Growth Strategies in the UK Virology and Bacteriology Testing Market 2014: Supplier Shares and Country Forecasts
  • Published:
  • Aug 25, 2014
  • USD 4300
  • 978 Pages

* Future Horizons and Growth Strategies in the US Virology and Bacteriology Testing Market 2014: Supplier Shares and Country Forecasts
  • Published:
  • Aug 25, 2014
  • USD 6400
  • 1037 Pages

* US Infectious Disease Molecular Diagnostics Market: Country Forecasts, Supplier Shares, Emerging Technologies, Competitive Landscape
  • Published:
  • Jul 29, 2014
  • USD 3900
  • 636 Pages

* European Infectious Disease Molecular Diagnostics Market: Country Forecasts, Supplier Shares, Emerging Technologies, Competitive Landscape
  • Published:
  • Jul 22, 2014
  • USD 7700
  • 700 Pages

Browse more Infectious Disease Market Research Reports

Pricing